Panbela Provides Business Update and Reports Q2 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Panbela Therapeutics, Inc. (PBLA) Misses Q2 EPS by $1.25
August 15, 2022 4:56 PM EDTPanbela Therapeutics, Inc. (NASDAQ: PBLA) reported Q2 EPS of ($1.51), $1.25 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Panbela Therapeutics, Inc. (PBLA) click here.
... More